Platinol-aq

Bristol-Myers Squibb Co. (Bristol) distributes cisplatin (known by the brand names of Platinol and Platinol-AQ ), which is approved for treatment of testicular, ovarian and bladder cancer. Bristol s patent listings in the Orange Book and related patent infringement suits demonstrate that doublepatenting and lengthy pendency of a patent application can generate an automatic 30-month stay on FDA approval of generic products close to their otherwise expected approval date. 

Platinol is sold as a freeze-dried (lyophilized) form of cisplatin, which is dissolved in water prior to injection. Platinol AQ is a sold as a solution of cisplatin with the water already added. Bristol received approval to market Platinol in 1978 and Platinol AQ in 1988. 

Cisplatin (Platinol, Platinol AQ) Oxaliplatin (Eloxatin) Procarbazine (Matulane)... 

Trade names Cisplatyl Plasticin Platiblastin Platinex Platinol (Bristol-Myers Squibb) Platinol-AQ Platistil Indications Carcinomas, lymphomas Category Alkylating agent Antineoplastic Half-life a phase 25-49 minutes (3 phase 58-73 hours Clinically important, potentially hazardous interactions with aldesleukin, atenolol, chlorothiazide, methotrexate, selenium, torsemide, zinc... 

Uniflox ciprofloxacin cyproheptadine ciprofloxacin Nimbex zuclopenthixol Cisplatyl, Plasticin, Platiblastin, Platinex, Platinol, Platinol-AQ, Platistil cisplatin praziquantel Celexa prilocaine immune globulin IV busulfan leucovorin cimetidine loratadine clarithromycin Leustatin cefotaxime... 

---